Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Accured Expenses (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Accured Expenses for 4 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 181.03% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$16.0 million, a 2203.81% decrease, with the full-year FY2025 number at -$16.0 million, down 2203.81% from a year prior.
  • Change in Accured Expenses was $6.4 million for Q4 2025 at Day One Biopharmaceuticals, up from $4.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $62.3 million in Q2 2024 to a low of -$51.9 million in Q3 2024.
  • A 4-year average of $285375.0 and a median of $1.8 million in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 3442.52% in 2024; the steepest drop was 4699.56% in 2024.
  • Day One Biopharmaceuticals' Change in Accured Expenses stood at $2.1 million in 2022, then soared by 178.0% to $5.9 million in 2023, then tumbled by 234.49% to -$7.9 million in 2024, then surged by 181.03% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Change in Accured Expenses are $6.4 million (Q4 2025), $4.1 million (Q3 2025), and $490000.0 (Q2 2025).